176 related articles for article (PubMed ID: 31366023)
1. Transactivation Function-1-Mediated Partial Agonist Activity of Selective Estrogen Receptor Modulator Requires Homo-Dimerization of the Estrogen Receptor α Ligand Binding Domain.
Arao Y; Korach KS
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31366023
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor α L543A,L544A mutation changes antagonists to agonists, correlating with the ligand binding domain dimerization associated with DNA binding activity.
Arao Y; Hamilton KJ; Coons LA; Korach KS
J Biol Chem; 2013 Jul; 288(29):21105-21116. PubMed ID: 23733188
[TBL] [Abstract][Full Text] [Related]
3. The physiological role of estrogen receptor functional domains.
Arao Y; Korach KS
Essays Biochem; 2021 Dec; 65(6):867-875. PubMed ID: 34028522
[TBL] [Abstract][Full Text] [Related]
4. The F domain of estrogen receptor α is involved in species-specific, tamoxifen-mediated transactivation.
Arao Y; Korach KS
J Biol Chem; 2018 Jun; 293(22):8495-8507. PubMed ID: 29632071
[TBL] [Abstract][Full Text] [Related]
5. Transactivation Function-2 of Estrogen Receptor α Contains Transactivation Function-1-regulating Element.
Arao Y; Coons LA; Zuercher WJ; Korach KS
J Biol Chem; 2015 Jul; 290(28):17611-27. PubMed ID: 26028650
[TBL] [Abstract][Full Text] [Related]
6. The genomic regulatory elements for estrogen receptor alpha transactivation-function-1 regulated genes.
Arao Y; Hamilton KJ; Grimm SA; Korach KS
FASEB J; 2020 Dec; 34(12):16003-16021. PubMed ID: 33064339
[TBL] [Abstract][Full Text] [Related]
7. Structural insights into Resveratrol's antagonist and partial agonist actions on estrogen receptor alpha.
Chakraborty S; Levenson AS; Biswas PK
BMC Struct Biol; 2013 Oct; 13():27. PubMed ID: 24160181
[TBL] [Abstract][Full Text] [Related]
8. Coactivators PGC-1beta and SRC-1 interact functionally to promote the agonist activity of the selective estrogen receptor modulator tamoxifen.
Kressler D; Hock MB; Kralli A
J Biol Chem; 2007 Sep; 282(37):26897-26907. PubMed ID: 17631495
[TBL] [Abstract][Full Text] [Related]
9. N-terminal transactivation function, AF-1, of estrogen receptor alpha controls obesity through enhancement of energy expenditure.
Arao Y; Hamilton KJ; Lierz SL; Korach KS
Mol Metab; 2018 Dec; 18():68-78. PubMed ID: 30287090
[TBL] [Abstract][Full Text] [Related]
10. Recruitment of histone deacetylase 4 to the N-terminal region of estrogen receptor alpha.
Leong H; Sloan JR; Nash PD; Greene GL
Mol Endocrinol; 2005 Dec; 19(12):2930-42. PubMed ID: 16051668
[TBL] [Abstract][Full Text] [Related]
11. Agonist-like SERM effects on ERalpha-mediated repression of MMP1 promoter activity predict in vivo effects on bone and uterus.
Scafonas A; Reszka AA; Kimmel DB; Hou XS; Su Q; Birzin ET; Kim S; Chen HY; Tan Q; Roher SP; Dininno F; Hammond ML; Rodan GA; Towler DA; Schmidt A
J Steroid Biochem Mol Biol; 2008 Jun; 110(3-5):197-206. PubMed ID: 18508261
[TBL] [Abstract][Full Text] [Related]
12. Role of aspartate 351 in transactivation and active conformation of estrogen receptor alpha.
Kim JH; Lee MH; Kim BJ; Kim JH; Han SJ; Kim HY; Stallcup MR
J Mol Endocrinol; 2005 Dec; 35(3):449-64. PubMed ID: 16326832
[TBL] [Abstract][Full Text] [Related]
13. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex.
Liu H; Lee ES; Deb Los Reyes A; Zapf JW; Jordan VC
Cancer Res; 2001 May; 61(9):3632-9. PubMed ID: 11325832
[TBL] [Abstract][Full Text] [Related]
14. Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay.
Arao Y; Korach KS
J Vis Exp; 2018 Dec; (142):. PubMed ID: 30614492
[TBL] [Abstract][Full Text] [Related]
15. In silico design of peptidic inhibitors targeting estrogen receptor alpha dimer interface.
Chakraborty S; Cole S; Rader N; King C; Rajnarayanan R; Biswas PK
Mol Divers; 2012 Aug; 16(3):441-51. PubMed ID: 22752657
[TBL] [Abstract][Full Text] [Related]
16. Structural insights into selective agonist actions of tamoxifen on human estrogen receptor alpha.
Chakraborty S; Biswas PK
J Mol Model; 2014 Aug; 20(8):2338. PubMed ID: 25060147
[TBL] [Abstract][Full Text] [Related]
17. The 2.0 A crystal structure of the ERalpha ligand-binding domain complexed with lasofoxifene.
Vajdos FF; Hoth LR; Geoghegan KF; Simons SP; LeMotte PK; Danley DE; Ammirati MJ; Pandit J
Protein Sci; 2007 May; 16(5):897-905. PubMed ID: 17456742
[TBL] [Abstract][Full Text] [Related]
18. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment.
Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biochemical characterization of a series of 17α-perfluoroalkylated estradiols as selective ligands for estrogen receptor α.
Eignerová B; Sedlák D; Dracínský M; Bartunek P; Kotora M
J Med Chem; 2010 Oct; 53(19):6947-53. PubMed ID: 20812681
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for an unexpected mode of SERM-mediated ER antagonism.
Wu YL; Yang X; Ren Z; McDonnell DP; Norris JD; Willson TM; Greene GL
Mol Cell; 2005 May; 18(4):413-24. PubMed ID: 15893725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
